• 1
    Wallace JF, Weingarten SR, Chiou C-F, et al. The limited incorporation of economic analyses in clinical practice guidelines. J Gen Intern Med. 2002;17:20120.
  • 2
    Hayward RS, Wilson MC, Tunis SR, Bass EB, Guyatt G. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group. JAMA. 1995;274:5704.
  • 3
    Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med. 1993;329:12713.
  • 4
    Ramsey SD, McIntosh M, Sullivan SD. Design issues for conducting cost-effectiveness analyses alongside clinical trials. Annu Rev Public Health. 2001;22:12941.
  • 5
    Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283:211621.
  • 6
    Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies. Med Decis Making. 2000;20:45167.
  • 7
    Tunis SR, Hayward RSA, Wilson MC, et al. Internists' attitudes about clinical practice guidelines. Ann Intern Med. 1994;120:95663.
  • 8
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:12538.
  • 9
    Patrick D, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press; 1993:2702.
  • 10
    Kopec JA, Schultz SE, Goel V, Ivan Williams J. Can the health utilities index measure change? Med Care. 2001;39:56274.
  • 11
    Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:6229.
  • 12
    Azimi NA, Welch HG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med. 1998;13:6649.
  • 13
    Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282:14537.
  • 14
    Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med. 1998;339:6739.
  • 15
    Mullins CD, Wang J, Palumbo FB, Stuart B. The impact of pipeline drugs on drug spending growth. Health Aff (Millwood). 2001;20:2105.
  • 16
    Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In: SloanFA, ed. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. New York: Cambridge University Press; 1995:7797.
  • 17
    Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J. 1993;148:9137.
  • 18
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:47381.
  • 19
    Sullivan SD, Lyles A, Luce B, Gricar J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organizations. J Manag Care Pharmacy. 2001;7:27282.